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ABSTRACT
Mitochondrial diseases are frequently associated
with mutations in mitochondrial DNA (mtDNA). In
most cases, mutant and wild-type mtDNAs coex-
ist, resulting in heteroplasmy. The selective elimi-
nation of mutant mtDNA, and consequent enrich-
ment of wild-type mtDNA, can rescue pathological
phenotypes in heteroplasmic cells. Use of the mi-
tochondrially targeted zinc finger-nuclease (mtZFN)
results in degradation of mutant mtDNA through
site-specific DNA cleavage. Here, we describe a
substantial enhancement of our previous mtZFN-
based approaches to targeting mtDNA, allowing
near-complete directional shifts of mtDNA hetero-
plasmy, either by iterative treatment or through finely
controlled expression of mtZFN, which limits off-
target catalysis and undesired mtDNA copy number
depletion. To demonstrate the utility of this improved
approach, we generated an isogenic distribution of
heteroplasmic cells with variable mtDNA mutant level
from the same parental source without clonal se-
lection. Analysis of these populations demonstrated
an altered metabolic signature in cells harbouring
decreased levels of mutant m.8993T>G mtDNA, as-
sociated with neuropathy, ataxia, and retinitis pig-
mentosa (NARP). We conclude that mtZFN-based ap-
proaches offer means for mtDNA heteroplasmy ma-
nipulation in basic research, and may provide a strat-
egy for therapeutic intervention in selected mito-
chondrial diseases.
INTRODUCTION
Mitochondria are ubiquitous organelles within the eukary-
otic domain, acting as a hub for numerous metabolic path-
ways and biochemical processes,most notably that of oxida-
tive phosphorylation (OXPHOS). Mitochondria contain a
relatively small, double-stranded, multi-copyDNA genome
(mtDNA). Human mtDNA is a 16.5 kb circular molecule
from which thirteen proteins and all tRNAs and rRNAs
necessary for their expression are produced (1). All pro-
teins encoded by human mtDNA are essential, hydropho-
bic, core subunits of the OXPHOS complexes.
Mutations in protein or RNA coding genes and regu-
latory elements of mtDNA often have severe biochemical
consequences, resulting in mitochondrial disease. Such dis-
orders frequently present with a heteroplasmic population
of mtDNA, where typically >50% of mtDNA molecules
bear a pathogenic mutation while the remainder is of the
unaffected wild-type (2). Currently there are no effective
treatments for mtDNA-mediated disease, and so novel ap-
proaches to therapy have been sought. One such approach,
through various means, entails the selective degradation of
pathogenic mtDNA in a heteroplasmic population (3,4).
Such degradation results in a heteroplasmic shift, altering
the proportion of mutated : wild-type mtDNA following
restoration of copy number. The validity of this approach
was first ascertained using mitochondrially targeted restric-
tion endonucleases (mtREs), re-directed prokaryotic en-
zymes that bind and cleave specific DNA sequences with
exceptional efficiency and fidelity (5–12). Unfortunately,
only a very limited number of disease-causative mutations
produce unique restriction sites within mtDNA, and re-
striction endonucleases are essentially impossible to re-
engineer, either ab initio or in situ. Another reagent, also
capable of such selective degradation, is the mitochondri-
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ally targeted engineered zinc finger-nuclease (mtZFN), a
chimeric enzyme consisting of a Cys2His2 zinc finger pro-
tein (ZFP), conveying DNA sequence specificity, conju-
gated to the FokI c-terminal catalytic domain, with addi-
tional mitochondrial targeting sequence (MTS) and nuclear
export signal (NES) peptides ensuring exclusive mitochon-
drial localisation (13–15). Importantly, ZFPs can be engi-
neered to bind virtually any DNA sequence, overcoming
the targeting limitations raised in earlier work with mtREs
(16,17). An alternative, engineered DNA binding technol-
ogy, the Xanthomonas-derived transcription activator-like
effector (TALE), has also been reported to produce similar
effects on mtDNA heteroplasmy in comparable cybrid cell
models when combined with the broadly interchangeable
nucleolytic and mitochondria targeting components used
in mtZFN, termed the mitochondrially targeted TALE-
nuclease (mitoTALEN) (18–20).
In previous reports, we have described the construction,
engineering and delivery of ZFPs or early ZFN designs to
mitochondria (15,21–23). Most recently, we have reported
our current heterodimeric mtZFN architecture, capable of
inducing modest shifts of mtDNA heteroplasmy in both
m.8993T>G point mutation and ‘common deletion’ cybrid
cell models, producing a phenotypic rescue in the latter (24).
In this work we describe the development of an approach
to significantly enhance heteroplasmic shifts of mtDNA us-
ing mtZFN in a cybrid cell model bearing the m.8993T>G
mutation; this mutation results in L217R substitution at a
highly conserved residue in subunit a ofATP synthase, asso-
ciated with neuropathy ataxia retinitis pigmentosa (NARP)
syndrome (25). We compare the efficiency of our enhanced
mtZFN strategy with that offered by alternative approaches
to shifting mtDNA heteroplasmy with mitochondrially tar-
geted nucleases (mtREs and TALENs). Finally, we show
that our improved mtZFN approach produces physiologi-
cal rescue of the m.8993T>Gmodel, revealing a substantial
metabolic shift between healthy and disease states.
MATERIALS AND METHODS
Plasmids and constructs
Constructs encoding mtZFN(+/−), mtTALEN(+/−) and
mt-XmaI were as reported for the second generation
mtZFN (mtZFN2G) in previous work, with the exception of
the DNAbinding domains, and cleavage domain in the case
of mtXmaI (24). The mtZFN(+/−) and mtTALEN(+/−)
constructs contain modified FokI domains (ELD/KKR)
that exhibit efficiency comparable to the wild-type nuclease,
but with a >40-fold reduction in homodimer activity (26).
These plasmids are available through the Addgene reposi-
tory (https://www.addgene.org/Michal Minczuk/). All sub-
cloning was carried out in pcDNA3.1(−) (Invitrogen). For
experiments where FACS was used, constructs bearing the
HA epitope tag were cloned into pcmCherry3.1(−) between
5′ XbaI and 3′ KpnI sites; constructs bearing the FLAG
epitope tag were cloned into pTracer CMV/Bsd between
5′ and 3′ PmeI sites (Life Technologies). For further detail,
please see our recent methods paper (27). TALE domains
were assembled according to the Unit Assembly method
(28) and verified by DNA sequencing. In an attempt to en-
courage cleavage of mutant mtDNA and discourage cleav-
age of wild-typemtDNA, the TALEdomains were designed
such that the mutant G was in the 5′ half of the target se-
quence (29).
Maintenance and transfection of mammalian cell lines
Human osteosarcoma 143B cell lineages were used in this
work. Cells were cultured in Dulbecco’s Modified Eagle’s
Medium (DMEM) containing 2 mM L-glutamine, 110
mg/L sodium pyruvate (Life Technologies) and 10% FCS
(PAA Laboratories). Cells were transfected with indicated
plasmids using Lipofectamine 2000 to the manufacturer’s
instructions. When spiking media with tetracyclines, cells
were transfected in media without the drug, and this me-
dia was replaced with drug supplemented media after 5 h.
After FACS at 24 h post-transfection, cells were returned
to media without drug supplementation for the remainder
of the experiment. In the case of stably transfected cells,
DMEM as previously described, was supplemented with 1
mg/ml neomycin and applied to transfectants 24 h post-
transfection. Cells were passaged for ∼18 days, and contin-
ued cultures of such cell lines were grown in DMEM as pre-
viously described, supplemented with 300g/ml neomycin.
The m.8993T>G cybrid cells were gifted by Prof. Eric
Schon.
Cell fractionation
Fractionation experiments were performed as previously
described in (30).
Immunodetection of proteins
Localisation of proteins by immunofluorescence was car-
ried out in fixed 143B cells as previously described (22). Im-
ages were captured using a Zeiss LSM 880 confocal micro-
scope.
The following antibodies were used for immunofluores-
cence experiments in this work: mouse anti-TOM22 (Ab-
cam, ab10436, 1:250), Alexafluor-594 anti-mouse (Molec-
ular Probes, A11005, 1:1000), rabbit anti-TFAM (gifted
by Prof. Rudolf Wiesner, 1:500), Alexafluor-405 anti-rabbit
(Molecular Probes, A31553, 1:1000), rat anti-HA (Roche,
11867431001, 1:500), Alexafluor-488 anti-rat (Molecular
Probes, A11006, 1:1000). Mounting medium used was
either ProLong Gold Antifade Mountant (Molecular
Probes), or ProLong Gold Antifade Mountant with DAPI
(Molecular Probes).
For western blot analyses, ∼20 g of extracted proteins
were resolved on SDS-PAGE 4–12% bis-tris gels (Life Tech-
nologies). The following antibodies were used for western
blotting in this work: mouse anti-FLAG (Sigma, F1804,
1:2000), rabbit anti-FLAG (Sigma, F7425, 1:2000), rat anti-
HA (Roche, 11867431001, 1:1000), rabbit anti-Histone H4
(Abcam, ab10158, 1:5000), rabbit anti-SSB1 (kindly gifted
by Prof D. Kang, 1:4000), mouse anti-TOM22 (Abcam,
ab10436, 1:5000), mouse anti-GAPDH (Abcam, ab9484,
1:10 000), goat anti-rabbitHRP (Promega,W401B, 1:2000),
goat anti-mouse HRP (Promega, W402B, 1:2000), goat
anti-rat HRP (Santa Cruz, SC2065, 1:1000).
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FACS, mtDNA heteroplasmy and copy number analyses
Methods used to sort cells and assessmtDNAheteroplasmy
and copy number are described in detail in our recent meth-
ods paper (27). All FACSwas carried out at the NIHRBRC
Cell Phenotyping Hub, Cambridge, UK.
Ultra-deep mtDNA amplicon re-sequencing
A single 682 bp amplicon, corresponding to nt.8657-9339 of
human mtDNA encompassing the mtZFN target site and
∼340 bp upstream and downstream regions of the predicted
breakpoint, was produced by PCR using KOD polymerase
(Toyobo) according to the manufacturer’s instructions with
a previously published primer pair (24,27). This PCRampli-
con was then subjected to IlluminaNextera sample process-
ing and 300-cycle paired-end sequencing using an Illumina
MiSeq instrument.
Paired-end sequences were aligned to the rCRS mito-
chondrial genome (NC 012920) using BWA (MEM mode)
(31) and sorted using Picard tools. Read qualities and align-
ments were evaluated using Mpileup of SAM tools (32).
Reads were discarded if they had a mapping phred score of
less than 30, and bases were ignored if they had a base qual-
ity phred score of less than 30.All readswere included, with-
out subsampling. To detect variants in mtDNA, the out-
put of Mpileup was analysed using VarScan (v2.3) (33) in
SNP and indelmodes, with aminimumvariant frequency of
0.05%, and minimum depth of 1000 reads. Variants with a
frequency of <0.5% were considered likely non-significant,
as the distribution of each of the four bases suggested this
was the limit of sequencing accuracy.
Oxygen consumption rate measurements
Oxygen consumption rate (OCR) was measured us-
ing the real time flux analyser XF-24e (Seahorse
Bioscience). For these experiments 6 × 104 cells were
treated with 1 M Oligomycin, 2 M Carbonyl cyanide-
p-trifluoromethoxyphenylhydrazone (FCCP), 1 M
Rotenone and 1 M Antimycin A (all purchased from
Sigma-Aldrich). At the end of the run cells were lysed
using RIPA buffer (25 mM Tris–HCl pH 7.6, 150 mM
NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS).
Protein content for each well was measured using BCA
kit (Pierce) according to the manufacturer’s instructions.
OCR was normalised to total protein content. The extent
of ATP-linked mitochondrial respiration was obtained
by calculating the ratio between OCR in the presence
or absence of Oligomycin. Data were obtained from 3
independent experiments and presented as mean ± SEM.
Statistical analysis was carried out with Prism Graphpad
software by applying one-way ANOVA and Tukey post-hoc
test (FDR = 0.05).
Liquid chromatography coupled to mass spectrometry (LC–
MS) metabolomic analysis
For metabolomic studies, 1 × 105 cells were plated onto
a 12-well plate and cultured in standard conditions for
24 h. Media was then replenished and after 24 h intra-
cellular metabolites were extracted as previously described
(34). LC–MS analysis was performed on a QExactive Or-
bitrap mass spectrometer coupled to a U3000 LC system
(Thermo). The liquid chromatography system was fitted
with a Sequant Zic-pHilic (150 mm × 2.1 mm, internal di-
ameter 3.5 m) with guard column (20 mm × 2.1 mm, in-
ternal diameter 3.5 m) fromHiChrom, Reading, UK. The
mobile phase was composed of 20 mM ammonium carbon-
ate and 0.1% ammonium hydroxide in water (solvent A),
and acetonitrile (solvent B). The flow rate was set at 180
l x min−1 with the following gradient: 0 min 80% B, 28
min 20% B, 29 min 80% B, 45 min 80% B. The mass spec-
trometer was operated in full MS and polarity switching
mode. Samples were randomized in order to avoid machine
drift and blinded to the operator. The acquired spectra were
analysed using XCalibur Qual Browser and XCalibur Quan
Browser softwares (Thermo Scientific) by referencing to an
internal library of compounds. Integrated metabolites were
normalised on totalmetabolite intensity per sample and sta-
tistically significant metabolites were obtained by applying
ANOVA and Tukey’s post-hoc test between samples (n =
4). Statistical analysis of metabolomic data was carried out
with R software (FDR = 0.05).
Energy charge state analysis
Energy charge state analysis for cybrids cells was calculated
using values for adenosine phosphate species as detected
by LC-MS, expressed as (ATP + 12 ADP)/(AMP + ADP
+ ATP), by the established method (35). The energy charge
for most cell types typically ranges from 0.8 to 0.95.
RESULTS
Modifying mtDNA heteroplasmy upon short-term expression
of mtZFNs
We addressed the feasibility of targeting pathogenic
mtDNA mutations using short-term, high expression of
mtZFN. To this end, a previously published mtZFN pair-
ing shown to be specific to the m.8993T>G mutation,
NARPd(+) and COMPa(−) (21,24), were cloned into vec-
tors that co-express fluorescent marker proteins (mCherry
for mtZFN(+), GFP for mtZFN(−)) enabling fluorescence
activated cell sorting (FACS) of transiently transfected cells
(Figure 1A and B). Such a strategy allows for much greater
temporal resolution of nuclease activity in mitochondria
than transfection/selection approaches, with increased con-
fidence in the homogeneity of samples analysed (27). In
these experiments, we included additional control mtZFNs
that are delivered to mitochondria but contain ZFP do-
mains untargeted to mtDNA (utZFN(+)/(−)), serving as
an indicator of non-specific or off-target activity. We trans-
fected constructs and empty vectors into 143B cybrid cells
bearing ∼80% m.8993T>G mtDNA (N80), which were
subjected to FACS at 24 h post-transfection, enriching the
population of cells expressing the transfected constructs.
After FACS, we harvested a subset of cells and seeded
the remaining transfectants for continued culture, collect-
ing these cells at 18 days and 28 days post-transfection
for mtDNA heteroplasmy and copy number analyses (Fig-
ure 1A). The m.8993T>G mutation produces a unique
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Figure 1. Strategy for targeting them.8993T>GNARPmutation usingmtZFNand analysis of heteroplasmy and copy number upon short-term expression
of mtZFNs. (A) Schematic of the general workflow for experiments that involve transient transfection of heteroplasmic cells with plasmids co-expressing
mtZFN monomers and fluorescent marker proteins, FACS-based selection of cells expressing both mtZFN monomers and phenotypic evaluation of
mtZFN-treated cells. The technical details and plasmids are as described in (27). (B) Detailed schematic of strategy for selective degradation of m.8993T>G
mtDNA using mtZFN. Conventional dimeric, engineered mtZFN are directed to sequence adjacent to (COMPa, green) or including (NARPd, red) the
mutated base position. Both monomers should bind the substrate only when the indicated nucleotide is mutated and not to the wild-type sequence. DNA
double strand breaks should only be introduced into the mutant mtDNA molecule, leading to a shift in heteroplasmy. (C) Last cycle hot PCR restriction
fragment length polymorphism (RFLP) analysis of mtDNA from FACS-enriched cells transiently expressing indicated mtZFN construct pairs. 143B and
N100 are included as wild-type and 100% mutant digestion controls, respectively. (D) Quantification of RFLP heteroplasmy data from several biological
replicates of FACS-enriched cells transiently transfected with mtZFN or control vectors. Data presented are frommeasurements made at 24 h, 18 days and
28 days post-transfection, as indicated. Statistical analyses were carried out using a two-tailed Student’s t-test, P = 0.027 (24h); P = 0.00167 (18 days); P
= 0.00146 (28 days); n = 3. ‘% untr. cells” indicates the baseline heteroplasmy of the N80 cell line used in these experiments. (E) Analysis of mtDNA copy
number, performed by qPCR in quadruplicate, from samples tested in (C). Error bars = 1 S.D. (F) Wild-type mtDNA heteroplasmy shifts upon iterative
expression and recovery cycles of mtZFN pairing NARPd(+)/COMPa(−). Inset; quantification of fold-changes in mtDNA heteroplasmy for mtZFNs and
controls for each iteration of transfection/FACS/recovery. Measurements of heteroplasmy presented were taken 28 days post-transfection. ‘% untr. cels’
indicates the baseline heteroplasmy of the N80 cell line used in these experiments.
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SmaI/XmaI restriction site, and heteroplasmy of sorted
cells was determined using a last cycle hot polymerase
chain reaction (LCH-PCR) assay, followed by SmaI re-
striction fragment length polymorphism (RFLP), as previ-
ously described (24,27) (Figure 1C). This assay indicated
that the NARPd(+)/COMPa(−) mtZFN pairing was ca-
pable of producing a modest mtDNA heteroplasmy shift,
from ∼22% to ∼40% wild-type mtDNA, as measured at
24 h, which remained stable 18 days and 28 days post-
transfection (Figure 1D). This result is broadly in line with
our previously published data on this optimized mtZFN
pairing, obtained from experiments examining the effects of
long-termmtZFN expression facilitated by antibiotic selec-
tion (24). However, copy number measurements from these
cells indicated a significant depletion of totalmtDNA levels,
to ∼15% of control, at 24 h post transfection, recovering to
∼50% of control by 18 days post-transfection and achiev-
ing parity with control by 28 days post-transfection (Fig-
ure 1E). Interestingly, the utZFN(+)/(−) pairing did not in-
duce a shift in heteroplasmy, though still produced a large
depletion of mtDNA copy number, to ∼25% of control at
24 h post-transfection, increasing to ∼65% of control at 18
days post-transfection and recovering to parity with control
by 28 days post-transfection (Figure 1D and E). To ensure
that the RFLP assay used was not confounded by repair
ofmtDNAmolecules through non-homologous end joining
(NHEJ), whichmight result in abolition of the SmaI restric-
tion site, we performed ultra-deep re-sequencing of the PCR
amplicon used for RFLP. This analysis did not detect any
unexpected sequence variants or variation in insertion or
deletion formation in mtZFN treated cells compared with
controls, confirming the fidelity of the RFLP assay (Sup-
plementary Figure S1). That repaired molecules were un-
detectable at such a sequencing depth strongly suggests ei-
ther a non-existent or extremely inefficient NHEJ double-
strand break repair pathway in mammalian mitochondria.
These data, taken together, suggest that although short-
term, high-dosage expression of mtZFNs produce signifi-
cant shifts in mtDNA heteroplasmy, substantial off-target
effects were occurring in these conditions, leading to unde-
sired mtDNA copy number depletion.
Iterative treatment of m.8993T>G with mtZFN results in a
near-complete heteroplasmy shift
Next, we set out to determine the effect of repeated mtZFN
treatments on mtDNA heteroplasmy shifting. To this end,
we performed several sequential rounds of transfection and
recovery using the m.8993T>G heteroplasmic cells and
NARPd(+)/COMPa(−) mtZFNs. Briefly, this consisted of
transfection and selection of transfectants by FACS at 24
h, followed by a 28 day recovery period to allow mtDNA
copy number repletion, at which point heteroplasmy was
measured and cells were re-transfected. Beginning withN80
cells, using four iterative cycles of transfection and recovery,
this approach was capable of producing a cumulative shift
in heteroplasmy from ∼80% to ∼7% m.8993T>G mtDNA
(Figure 1F). These results demonstrated that sequential,
short-term mtZFN treatments, despite the significant off-
target activity observed (Figure 1E), could achieve near-
complete elimination of mtDNA mutations.
A FACS approach to modify dosage of mtZFN
Having identified excessive depletion of mtDNA copy num-
ber as potentially obstructive to our purpose, we intended
to test whether a lower concentration of mtZFNs in mito-
chondria could minimise this effect. To this end, we modi-
fied our previous FACS-based approach, isolating hetero-
plasmic m.8993T>G cells transiently expressing variable
quantities of mtZFN by altering the gating strategy em-
ployed. We were able to extract two distinct populations of
transiently transfected cells, termed ‘low’ and ‘high’ (Figure
2A), which, we hypothesised, would express varied quan-
tities of the transfected constructs in line with detected
fluorescence. N80 cells were transiently transfected with
NARPd(+)/COMPa(−) mtZFN constructs or empty vec-
tors, and were subjected to FACS after 24 h with transfec-
tants separated into ‘high’ and ‘low’ populations. Western
blotting revealed differences in mtZFN protein expression
levels between these two populations (Figure 2B). At 24 h
post-transfection, in the ‘low’ expressingmtZFN condition,
we observed an increase in effectiveness of mtDNA hetero-
plasmy shifting, from ∼22% to ∼55% wild-type mtDNA
(Figure 2D), as compared to the total transfectant pool,
which shifted from∼22% to∼40% wild-type mtDNA (Fig-
ure 1D). We also observed an improved rate of mtDNA
copy number recovery in the ‘low’ expressing population,
where parity with control was achieved at 18 days post-
transfection (Figure 2E), as compared to the total trans-
fectant pool, which reached parity with control at 28 days
post-transfection (Figure 1E). Heteroplasmic shifts in these
cells remained stable at 18 and 28 days post-transfection
(Figure 2D). However, heteroplasmic shifts observed in the
‘high’ expressing mtZFN condition were substantially di-
minished, to levels that were no longer considered statis-
tically significant (Figure 2D). We also observed greater
mtDNA copy number depletion in the ‘high’ expressing
conditions, to ∼7% of control, at 24 h post-transfection, as
compared to the ‘low’ expressing transfectant population,
which depleted mtDNA copy number to ∼24% of control
(Figure 2E). These data suggested that an optimised ‘dose’
of mtZFNs can enhance mtDNA heteroplasmy shifts and
minimise mtDNA copy number depletion.
A hammerhead ribozyme-based approach for fine control of
mtZFN expression
As alterations of mtZFN concentration in mitochondria
were observed to produce significantly improved shifts in
mtDNA heteroplasmy, with reduced deleterious effects on
mtDNA copy number, we sought a method to exercise
greater control over protein expression levels. Recent ad-
vances in RNA chemistry have yielded an array of engi-
neered hammerhead ribozymes (HHRs), modified bacte-
rial ribozymes that constitutively cleave the RNA species
within which they are contained. In the case of a eukaryotic
mRNA, if placed upstream of the poly(A) signal, HHR-
mediated cleavage produces a 3′ end that is susceptible to
degradation, greatly reducing protein expression from this
mRNA (36). This catalytic RNA element has recently been
combined with a RNA aptamer, specific to the antibiotic
drug tetracycline. Binding of tetracycline rigidifies the RNA
D
ow
nloaded from
 https://academ
ic.oup.com
/nar/article-abstract/44/16/7804/2460548 by U
niversity of G
lasgow
 user on 10 M
arch 2020
Nucleic Acids Research, 2016, Vol. 44, No. 16 7809
37
37
MW
[kDa]
37
NARPd(+)
COMPa(-)
vector
vector WT N
10
0
NARPd(+)
COMPa(-)
vector
vector
23 22 49 35
23 23 47 35
23 21 3149
C
0
20
40
60
80
100
120
140
160
m
tD
N
A
 c
op
y 
nu
m
be
r [
%
]
18 days
28 days
24 hours
NARPd(+)
COMPa(-)
vector
vector
E
*
NARPd(+)
COMPa(-)
vector
vector
% untr.
    cells
0
10
20
30
40
50
60
70
80
90
100
W
ild
-ty
pe
 m
tD
N
A 
[%
]
α β-actin
α HA [Nd(+)]
α FLAG [Ca(-)]
CBB
% WT
- Wild-type
- m.8993T>G 
% WT
- Wild-type
- m.8993T>G 
% WT
- Wild-type
- m.8993T>G 
24
 h
ou
rs
18
 d
ay
s
28
 d
ay
s
24h 28d18d 24h 28d18d 24h 28d18d 24h 28d18d
Low High HighLow
* * *
-p
-m
A B
D
Figure 2. Dosage of mtZFN substantially alters the efficiency of heteroplasmy shifting and mtDNA copy number depletion/repletion profiles. (A) Repre-
sentative dot plot indicating a typical FACS gating strategy used to separate ‘high’ and ‘low’ mtZFN-expressing transfectants. (B) Western blot analysis
of total cellular proteins from FACS-enriched samples at 24 h post-transfection by SDS-PAGE, probing for mtZFN expression with antibodies to the
HA (NARPd (Nd)) or FLAG (COMPa (Ca)) epitopes. -actin and a section of Coomassie stained gel (CBB) are shown as loading controls. p, precursor
isoform; m, mature isoform. (C) Last cycle hot PCRRFLP of mtDNA from cells transiently expressing ‘high’ or ‘low’ quantities of mtZFN or control vec-
tors. (D) Quantification of collated heteroplasmy data from several biological replicates of transient mtZFN or control vector expression. Data presented
are from measurements made at 24 h, 18 days and 28 days post-transfection, as indicated. Statistical analyses were carried out using a two-tailed Student’s
t-test, P = 0.044 (‘low’ 24 h); P = 0.032 (‘low’ 18 days); P = 0.011 (‘low’ 28 days); n = 3. ‘% untr. cells’ indicates the baseline heteroplasmy of the N80 cell
line used in these experiments. (E) Analysis of mtDNA copy number, performed by qPCR in quadruplicate, from samples tested in D. Statistical analyses
were carried out using a two-tailed Student’s t-test, P = 0.036 (mtZFN, 24 h). Error bars = 1 S.D.
structure and inhibits catalysis by the HHR (37). We incor-
porated the 3′K19 version of this HHR element into our
mtZFN(+)/(−) backbone, between the mtZFN ORF stop
codon and the bovine growth hormone (BGH) poly(A) site
(Figure 3A). Importantly, any such system of regulation ap-
plied equally to a bipartite catalytic mechanism is likely to
entail significant cooperative effects on the rate of nucle-
olytic cleavage, enabling a broad dynamic range of catalytic
control.
To assess the dynamic range of mtZFN dosage control
exerted by 3′K19 HHR, we transfected wild-type 143B cells
with a single mtZFN monomer (COMPa(-)), either with
or without the 3′ K19 HHR element. COMPa(−)HHR
transfected cells were grown in media supplemented with
various concentrations of tetracycline or doxycycline (Fig-
ure 3B). We enriched transfectants by FACS at 24 h post-
transfection, sorting GFP positive cells only. Western blot
analysis of COMPa(−) protein levels revealed a substantial
change in expression of the protein between various drug
concentrations, appearing broadly in line with the previ-
ously published data where cis-catalysis of mRNA by the
3′K19 HHR reduced expression of the transgene by ∼90%
(37). (Figure 3B). Expression of COMPa(−)HHR was not
altered in the presence of 250 Mdoxycycline, as compared
to COMPa(−)HHR in the presence of 0 M tetracycline,
demonstrating the specificity of the RNA aptamer for tetra-
cycline only. In these conditions, expression of mtZFN was
not detectable at 18 days or 28 days post-transfection (Sup-
plementary Figure S2).
Next, we transiently transfected N80 cells with the
NARPd(+)HHR/COMPa(-)HHR constructs, and
grew them for 24 h in media supplemented with dif-
ferent concentrations of tetracycline prior to FACS.
Analysis of m.8993T>G heteroplasmy at 24 h indi-
cated moderately enhanced shifts in cells transfected
with NARPd(+)HHR/COMPa(−)HHR constructs
as compared to mtZFN not containing 3′K19 HHR
(Supplementary Figure S3A). However, continued
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Figure 3. Dynamic control of mtZFN expression using a tetracycline-sensitive 3′ hammerhead ribozyme (HHR) reveals dosage-dependent effects on
heteroplasmy and mtDNA copy number depletion/repletion profiles. (A) Schematic of mtZFN transgene with the hammerhead ribozyme (HHR) incor-
porated. When transcribed, mRNA encoding mtZFN is constitutively degraded following HHR cleavage, resulting in substantially lower quantities of
translated protein. However, in the presence of tetracycline the HHR element is stabilized, inhibiting catalysis and producing larger quantities of translated
protein. CMV, cytomegalovirus promoter, MTS, mitochondrial targeting sequence, F, FLAG epitope tag, NES, nuclear export signal, BGH pA, bovine
growth hormone polyadenylation signal. (B) Western blot analysis of total cell lysates from FACS-enriched samples at 24 h post-transfection, probing for
expression of COMPa(−) mtZFN or COMPa(-)HHR mtZFN (FLAG) in the indicated concentrations of tetracycline (tet) or doxycycline (dox) in the
medium. -actin and a section of Coomassie stained gel (CBB) are shown as loading controls. p, precursor isoform; m, mature isoform. (C) Quantifica-
tion of collated heteroplasmy data from several biological replicates of transient mtZFN expression. Measurements made at 28 days post-transfection.
Filled black triangle indicates spectrum of tetracycline concentrations (0, 25, 250 M). n = 3, statistical analyses were undertaken using a two-tailed Stu-
dent’s t-test, P = 0.0015 (vector/mtZFN), P = 0.0002 (vector/mtZFN-HHR, 0 M), P = 0.009 (mtZFN-HHR, 0 M/mtZFN-HHR, 250 M). ‘% untr.
cells’ indicates the baseline heteroplasmy of the N80 cell line used in these experiments. (D) Analysis of mtDNA copy number, performed by qPCR in
quadruplicate, from samples tested in C. Statistical analyses were undertaken using a two-tailed Student’s t-test, P = 0.047. Error bars = 1 SD.
culture of m.8993T>G cybrid cells transfected with
NARPd(+)HHR/COMPa(−)HHR up to 28 days post-
transfection revealedmuchmore pronounced heteroplasmy
shifts towards wild-type mtDNA (Figure 3C and Supple-
mentary Figure S3B). Importantly, in conditions exhibiting
the lowest mtZFN expression levels (tetracycline-free
and 25 M), we observed a near-complete wild-type
heteroplasmy rescue, from ∼20% to ∼ 90% wild-type
mtDNA at 18 days post-transfection (Supplementary
Figure S3B), which was stable at 28 days (Figure 3C).
Treatment with NARPd(+)HHR/COMPa(−)HHR
mtZFN constructs without tetracycline was accompanied
by a less-pronounced mtDNA copy number depletion
at 24 h post-transfection (21% of control) as compared
to cells transfected with the same constructs exposed to
250 M tetracycline (12% of control) (Figure 3D). A
concurrent decrease in heteroplasmy shifting efficiency
was also observed with higher expression levels of HHR-
controlled mtZFNs, when comparing lower expressing
(tetracycline-free or 25 M) and higher expressing (250
M) conditions (Figure 3C). Similarly, the rate of mtDNA
copy number repletion was improved for HHR-controlled
mtZFN constructs exposed to 25 M or no tetracycline,
reaching parity with control by 18 days post-transfection
(Figure 3D). Additionally, we transiently transfected N80
cells with utZFN(+/−)HHR constructs in the absence of
tetracycline, observing that decreased levels of non-specific
nuclease expression reduce copy number depletion by
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>100% at 24 h post-transfection, with a substantially
improved mtDNA repopulation profile, regaining parity
with control at 18 days (Supplementary Figure S4). These
data demonstrated that manipulating dosage of mtZFNs,
through the incorporation of an engineered hammerhead
ribozyme, can improve degradation of pathogenic mu-
tations in heteroplasmic mtDNA populations by more
than 2-fold beyond uncontrolled, high dosages of mtZFNs
through mitigation of off-target catalytic events.
Comparing the mtDNA heteroplasmy shifting efficiency of
mtZFNs with alternative mitochondrially targeted nucleases
Next, we compared the efficiency of shifts in m.8993T>G
heteroplasmy produced by HHR-controlled mtZFNs with
those of a mtRE. To this end, we reproduced the HHR
dose-controlled experiments presented using amtRE,XmaI
(mt-XmaI) (Supplementary Figure S5A), which binds and
specifically cleaves the unique site produced in mtDNA by
the m.8993T>Gmutation (5′ CCCGGG ’3) at very high ef-
ficiency (10). N80 cells were transfected with mt-XmaI, mt-
XmaIHHRor control vector, grown inmedia supplemented
with various quantities of tetracycline and subjected to
FACS at 24 h, gating the mCherry positive population
only. Western blot analysis of these transfectants demon-
strated tetracycline dose-dependent expression of mt-XmaI
(Supplementary Figure S5B), comparable to that seen for
mtZFN (Figure 3B). Under both HHR-controlled and un-
restrained, CMV-driven expression conditions, mt-XmaI
produced a shift in heteroplasmy from 20% to ∼86% wild-
type mtDNA at 28 days post-transfection (Supplementary
Figure S5C and D). This shift was accompanied by a sig-
nificant depletion of mtDNA copy number in all expres-
sion conditions at 24 h, which regained parity with con-
trol at 18 days post-transfection (Supplementary Figure
S5E). Of interest, lower expression conditions, particularly
the tetracycline-free mt-XmaIHHR condition, appeared to
shift heteroplasmy to a lesser extent at 24 h (Supplementary
Figure S5F), displaying concomitantly less mtDNA copy
number depletion, though heteroplasmic shifts are essen-
tially identical by 28 days post-transfection, suggesting that,
unlike for mtZFN, limiting the concentration of mt-XmaI is
detrimental to heteroplasmy shifting activity.
We also attempted experiments using a mitochondrially
targeted TALE nuclease (mtTALEN) architecture of our
own design (Supplementary Figure S6A), essentially iden-
tical to the mitoTALEN design that has been reported pre-
viously (18,19). Our heterodimeric mtTALENs were effi-
ciently delivered to mitochondria, where they co-localised
with core mitochondrial nucleoid component TFAM (Sup-
plementary Figure S6B–D). We tested four distinct TALE
pairs targeted to m.8993T>G and control constructs that
contained TALE domains non-specific to mtDNA (ut-
TALEN) (Supplementary Figure S7A). None were able to
shift heteroplasmy to a statistically significant extent upon
high dose short-term expression, though all pairs depleted
mtDNAcopy number (Supplementary Figure S7B–D). The
effect on mtDNA copy number indicates that mtTALENs
are imported into themitochondrial matrix, consistent with
the cellular localisation studies (Supplementary Figure S6).
To investigate whether dosage dependent effects might
be governing the efficiency of these constructs, we took
the best mtTALEN pairing (which appeared to shift het-
eroplasmy in a single biological replicate) and conducted
FACS-gated ‘high’ and ‘low’ dosage control experiments
(Supplementary Figure S8A). These experiments demon-
strated no differences in heteroplasmy between high and
low expressing populations of this optimal mtTALEN pair-
ing (Supplementary Figure S8B,C), though a significant
increase in mtDNA copy number depletion was observed
upon high expression of mtTALEN (Supplementary Figure
S8D). The results of these experiments demonstrate that,
through limited expression strategies, mtZFN are capable
of shifting m.8993T>G heteroplasmy to a degree indis-
tinguishable from a restriction endonuclease, and that mt-
TALEN are unable to effectively target m.8993T>G.
Rescue of mtDNAm.8993T>G-associated mitochondrial de-
fect by mtZFNs is associated with metabolic rewiring
Next we set out to determine whether mtZFN-mediated
shifts in heteroplasmy of m.8993T>G mutant mtDNA
were associated with rescue of mitochondrial respiratory
function and changes in metabolic profile. The following
cell lines were assessed for physiological changes associ-
ated with their altered heteroplasmic states: control vector-
transfected N80 cells and N80-derived cells obtained fol-
lowing treatment with NARPd(+)HHR/COMPa(−)HHR
in 25 M (10%m.8993T>GmtDNA; N10) and in 250 M
tetracycline concentrations (45% m.8993T>G mtDNA;
N45). Oxygen consumption increased in both N45 andN10
compared to N80 (Figure 4A). Furthermore, genetic cor-
rection of m.8993T>GmtDNA increased both proportion
of mitochondrial respiration coupled to ATP production
and adenylate energy charge state (Figure 4B,C), indicating
a functional rescue of mitochondrial respiration following
heteroplasmy shift.
We then investigated whether heteroplasmy shift of
m.8993T>G mtDNA is associated with changes in cel-
lular metabolism. To this end we performed Liquid-
Chromatography coupled to Mass Spectrometry (LC-MS)-
based metabolomic analyses of N80, N45 and N10 cells.
Principal component analysis based on a matrix of 70
metabolites clearly separated the three cell lineages based
on their heteroplasmy level (Figure 4D), indicating that
substantial metabolic changes are associated with genetic
correction of m.8993T>G mtDNA. Univariate analysis of
individual metabolites (Supplementary Figure S9) demon-
strated that citrate and aconitate, two key mitochondrial
metabolites, were among the most increased metabolites in
both N45 and N10 compared to N80 (Figure 4E and Sup-
plementary Figure S9). These data suggested that the de-
fect of mitochondrial function in cells bearing high loads of
m.8993T>G mtDNA can be corrected by mtZFNs.
DISCUSSION
In this work, we strove to develop improved approaches
to haplotype-specific mtDNA heteroplasmy shifting using
mtZFNs. We undertook experiments with mtZFNs tar-
geted to them.8993T>Gmutation, causative ofNARP syn-
drome, using a well-investigated cybrid cell model. Through
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Figure 4. Treatment withmtZFN rescues themitochondrial defect associated withm.8993T>Gand is accompanied by rewiring of cellular metabolism. (A)
Oxygen consumption rates (OCR) in empty vector-transfected cybrid cells harbouring 80% of m.8993T>G (N80) and cells of the same origin transfected
with NARPd(+)-HHR/COMPa(−)-HHR with either 25 M (N10) or 250 M (N45) tetracycline present in the culture medium. These cell lines were
generated concurrently within a single experiment. Statistical analysis was undertaken using a two-tailed Student’s t-test (P = 0.0001865, n = 7). (B) ATP-
linked mitochondrial respiration in N80, N45 and N10 cells, calculated as the ratio of OCR in the presence or absence of oligomycin. (C) Energy charge
state analysis of N80, N45 and N10 cells, calculated using values for adenosine phosphate species detection by LC-MS by the established method (35). (D)
Principal Component Analysis (PCA) of intracellular metabolites from N80, N45 and N10 cells as measured by LC-MS-based metabolomics. Score plot
of principal component 1 and 2, explaining 55.7% and 16.1% of total variance, respectively, is shown. (E) Heatmap representation of intracellular levels of
citrate and aconitate in N80, N45 and N10 cells, as measured by LC–MS. Of note, citrate abundance was found to be significantly different between N80
and N45, as well as between N80 and N10, while aconitate was significantly upregulated in N10 compared to N80 cells (Supplementary Figure S8).
use of a FACS-based method for selecting populations
of transiently transfected cells (Figure 1A), we observed
that mtZFNs expressed at a high level (i.e. CMV-driven
expression) produce considerable depletions of mtDNA
copy number (Figure 1E), regardless of their effect on
mtDNA heteroplasmy (Figure 1C and D). Theoretically, if
themtZFNpair were to be perfectly specific tom.8993T>G
mtDNA, and exclusively cleave the mutant haplotype, it
would be expected that, in N80 cells, mtDNA copy num-
ber would be depleted to 20% of control, at its lowest
point, with a shift to 100% wild-type mtDNA achieved
upon recovery of copy number. Therefore, it was hypoth-
esised that substantial off-target effects are likely to be lim-
iting heteroplasmy-shifting efficiency. Despite the signifi-
cant mtDNA depletions observed in m.8993T>G-specific
mtZFN treatment, we demonstrated that iterative cycles
of transfection and recovery allowed stepwise increases in
wild-type mtDNA heteroplasmy, achieving a cumulative
shift from 20% to 93% wild-type mtDNA after four cycles
of treatment (Figure 1F).
To test the hypothesis of non-specific nuclease-DNA in-
teractions limiting the efficiency of heteroplasmy shifting,
we produced a system to compare conditions of higher
and lower mtZFN expression. The rationale for this was
that lower mitochondrial concentrations of a nuclease
would produce proportionately fewer off-target cleavage
events, potentially enhancing heteroplasmy shifts. By iso-
lating ‘high’ and ‘low’ expressing m.8993T>G cybrid cells
from the same transfection using FACS (Figure 2A), we
were able to produce cell populations with a modest al-
teration in mtZFN expression levels (Figure 2B). The pro-
portions of pre-import ‘precursor’ and post-import ‘ma-
ture’ isoforms of mtZFN were altered depending on ex-
pression level, with ‘high’ cell populations demonstrating
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an increased quantity of the precursor isoform, suggest-
ing temporary saturation of the mitochondrial protein im-
port apparatus. The ‘low’ expression levels were associated
with less-severe depletions of mtDNA copy number and a
concomitant improvement in heteroplasmy shifting (Figure
2C–E), enhancing the efficiency of the treatment by ∼100%
when compared with experiments where the entire transfec-
tant population was sorted and analysed en masse (Figure
1). Cells from the ‘high’ expression condition, transfected
with the same mtZFNs, demonstrated an abrogated capac-
ity to shift heteroplasmy, accompanied by a noticeable in-
crease in severity ofmtDNAcopy number depletion (Figure
2C and D).
With these data suggesting that relatively small changes
in mtZFN expression levels could drastically alter the effi-
ciency of their DNA-specific activity, we set out to gener-
ate a universal platform allowing dynamic control of tran-
sient mtZFN expression. To achieve this we incorporated a
self-cleaving 3′ hammerhead ribozyme (HHR) element, en-
gineered to include awell-characterised tetracycline-specific
RNA aptamer as a means of disinhibition (37), provid-
ing the basis for dynamic, dose-controlled expression of
mtZFNs within a transient expression system (Figure 3A).
The constitutive self-cleaving activity of the HHR cat-
alytic RNA greatly attenuated expression of the mtZFN
monomers, and addition of tetracycline to the culture
medium inhibited RNA cleavage, permitting expression of
mtZFNs to near CMV-driven levels (Figure 3B). The re-
duced mtZFN expression levels observed in tetracycline-
free or 25 M tetracycline conditions produced hetero-
plasmy shifts resulting in>4-fold greater quantities of wild-
type mtDNA compared with mock transfected cells (Fig-
ure 3C), and >2-fold greater quantities when compared
with experiments assessing the entire population of CMV-
driven mtZFN transfectants (Figure 1C–E). The severity
of mtDNA copy number depletion in these cells was also
greatly decreased (Figure 3D). Further, measurements of
copy number depletion in cells expressing various amounts
of utZFN(+/−) demonstrated that low levels of expression
improve the copy number depletion/repletion profile (Sup-
plementary Figure S4). These data confirm the relationship
between over-dosage of mtZFNs and loss of heteroplasmy
shifting efficacy, as a function of unintended mtDNA copy
number depletion through off-target effects. The precise na-
ture of off-target catalysis observed in these studies, whether
at the mutation site, at other similar sites or entirely non-
specific is uncertain, though experiments with utZFN and
utTALEN suggest that entirely non-specific nucleolytic ef-
fects form a substantial component of this milieu.
The comparisons made between mtZFN technology and
the better-investigated mitochondrially targeted restriction
endonucleases (5–12), in this case mt-XmaI, clearly indicate
that the capacity of XmaI to reject an incorrect substrate
and avoid off-target activity-mediated mtDNA copy num-
ber depletion is considerably greater than that of mtZFNs
(Supplementary Figure S5). This result is not unexpected,
given the published in vitro data on XmaI, which indicates
∼1000-fold greater affinity for canonical over non-cognate
sites, defined as a sequence where 1 of 6 nucleotides is al-
tered (38), as is the case for m.8993T>G. However, for
mtZFN expression limitation strategies to be capable of
achieving a shift in heteroplasmy of identical magnitude
to that produced by a mtRE is encouraging, particularly
with regard to future applications of this technology. Our
attempts to shift m.8993T>G heteroplasmy with a TALE-
based design were unsuccessful, as it appears that this site
in mtDNA is not easily targeted by this technology. This
lack of efficacy is likely due to the inability of TALE as-
semblies to act with single-nucleotide specificity at the tar-
get site, resulting in degradation of both wild-type and mu-
tant mtDNAmolecules at a similar rate. Of note, the major-
ity of previously published mitoTALENs have exploited a
key TALE binding constraint to their advantage, the neces-
sity for a thymidine base at position 0 of a DNA target site.
Without a T at position 0, binding of TALE domains can
be greatly impeded (39). As such, targeting heteroplasmic
mtDNA point mutations producing N>T or N>A substi-
tutions using a TALE-based architecture can be highly ef-
ficacious. However, such a strategy is not available in the
case of m.8993T>G. Furthermore, the sequence context in
which a mutation is present can also determine the effec-
tiveness of targeting using TALE-based systems. Specifi-
cally, the closer themutated base is to theN-terminal TALE
binding module, the more likely it is that the TALE will
be able to discriminate with single nucleotide specificity. As
a T at position 0 is highly preferred, the sequence context
of m.8993T>G does not permit placement of the muta-
tion site especially close to the N-terminal portion of the
TALE module, and this is a likely reason for the lack of
heteroplasmy shifting activity observed. We can also spec-
ulate as to the accessibility of this mtDNA target site by
mtTALENs, which may be compromised by m5C methyla-
tion, or other epigenetic modifications present in the target
sequence (40–43). However, our data still suggest the im-
portance of dosage control for these constructs, as we have
shown that a TALEN not specific to mitochondrial DNA
sequence, expressed at a high level inmitochondria, can pro-
duce substantial mtDNA copy number depletion (Supple-
mentary Figures S7 and S8).
Finally, to confirm that the changes in m.8993T>G mu-
tation load are associated with altered mitochondrial func-
tion, we performed a comprehensive metabolic charac-
terisation of cells with different, but stable levels of het-
eroplasmy. We found that correction of m.8993T>G mu-
tation is associated not only with increased basal mito-
chondrial respiration, but also with greater coupling of
mitochondrial oxygen consumption to ATP production
and improvements in energy charge state (Figure 4A–C).
These alterations of mitochondrial function presaged im-
portant consequences for cellular metabolism, and our
metabolomic analyses pointed to a comprehensive rewiring
of metabolism upon correction of the m.8993T>G muta-
tion, with citrate and aconitate among the most significant
metabolic rescues. Of note, production of citrate from ox-
aloacetate and acetyl-CoA is the first committed step of the
tricarboxylic acid (TCA) cycle. This reaction requires intact
mitochondrial function and favorable NAD+/NADH ra-
tio (44,45). Therefore, the gradual increase in citrate upon
correction of m.8993T>Gmutation can be interpreted as a
gradual restoration of TCA cycle activity underpinned by
rescue of mitochondrial function. However, we cannot ex-
clude that restoration of citrate and aconitate levels in N10
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can be explained by additional metabolic changes, beyond
increased citrate synthesis. Overall, these results are com-
patible with the notion that near-complete heteroplasmic
shifts, obtained through mtZFN treatment, not only cor-
rect the m.8993T>G mutation, but also the bioenergetic
and metabolic defects observed in cells bearing high levels
of mutated mtDNA.
Significant variation across a range of physiological mea-
sures is often detected between cell lines of variable ori-
gin bearing the same mtDNA mutations, or between cy-
brid clones from the same genetic source bearing the same
mtDNA mutation. It is apparent to most of the field that
inherent variation between cybrid clones, which would oth-
erwise be considered ‘isogenic’, can lead to uninterpretable
results. To evidence this, we have measured respiration
in an independently selected cybrid clone bearing 100%
m.8993T>G mtDNA (N100). N100 respired at levels sig-
nificantly higher than N80, N45 and N10, with commensu-
rate elevation in energy charge state (Supplementary Figure
S10), and was therefore deemed an inappropriate control in
these studies. We are inclined to suggest that the popula-
tion of cells generated using mtZFN and FACS-based se-
lection, where short-term expression of a mitochondrially
targeted nuclease leads to permanent changes in mtDNA
heteroplasmy, constitutes a more representative ‘isogenic
distribution’ of cells (rather than randomly-picked individ-
ual clones upon long-term selection) (46) from which the
genuine physiological impact of mtDNA mutations can be
teased. Therefore, rather than sounding the death knell for
cybrid cells, perhaps similar approaches to those described
in this work could be of benefit to groups studying cellular
physiology using cybrid models in the future.
Various approaches to shifting mtDNA heteroplasmy,
beyond those discussed in the body of this paper, have
been reported in the recent past. These include upregula-
tion of autophagy through over-expression of the ubiquitin
ligase Parkin (47) and restoration of wild-type mtDNA in
human cells bearing mtDNA rearrangements through ec-
topic overexpression of a yeast recombination enzyme (48).
There also exist reports describing the successful import of
synthetic, mutation-specific anti-sense RNA tomammalian
mitochondria for inhibition of pathogenic mtDNA replica-
tion (49,50). This work is based upon claims of harnessing a
naturally occurring RNA import mechanism for controlled
RNAdelivery intomammalianmitochondria. A crypticmi-
tochondrial import system for nucleus-encoded tRNAs, ob-
served in lower metazoans, has also been proposed to exist
in human cells, however the details of the components in-
volved remain ill-defined. Short synthetic RNAs, compris-
ing two domains of the yeast cytosolic tRNALys(CUU) (D-
arm and F-hairpin), have been claimed to be delivered into
human mitochondria using this cryptic mechanism (49).
Further, published data from the same group claim that 5S
cytosolic ribosomal RNA (5S rRNA) is localised to the mi-
tochondrial matrix, forming part of the mitochondrial ri-
bosome (51); it has also been proposed that fragments of
5S rRNA can function as a vector for delivering heterol-
ogous RNA into human mitochondria (52). Additionally,
the RNA component of the nuclear RNase P ribozyme
has been localised to human mitochondria, with its stem-
loop reported to direct the import of exogenous transcripts
into human mitochondria (53). However, reconciling re-
ports of efficient RNA import into mammalian mitochon-
dria with other available data is problematic. Firstly, mam-
malian mtDNA encodes a full complement of tRNAs nec-
essary for its expression (1), so, in principle, there is no func-
tional reason for import of nucleus-encoded tRNA into the
organelle. Secondly, recent structures of the large mitoribo-
somal subunit have confirmed that cytosolic 5S rRNA is
not a component of the human mitoribosome, with a mi-
tochondrially encoded tRNA residing in its predicted loca-
tion instead (54,55). Thirdly, it has been demonstrated that
human mitochondrial RNase P does not require a trans-
acting RNA for catalysis, but is composed of protein only
(56). In accordance with the above points, any mitochon-
drial import of synthetic RNA molecules, based on a nat-
urally occurring mechanism in human cells, would have to
be, at best, sporadic and inefficient.
The use of CRISPR/Cas9 in human mitochondria has
also been reported in conjunction with the previously men-
tioned inefficient (or deficient) and uncharacterised mam-
malian mitochondrial RNA import pathway (57). How-
ever, given the aforementioned constraints, until experi-
ments demonstrating synthetic RNA import into human
mitochondria can be widely and reliably reproduced by
other researchers, mitochondrial CRISPR/Cas9 should re-
main a promising yet unfulfilled method (58).
In summary, the developments described in this work,
demonstrating that heteroplasmy shifting activity of mi-
tochondrially targeted nucleases can be greatly enhanced
by minimising deleterious off-target effects, are likely to be
of value to the field. Despite being unable to demonstrate
this effect using mtTALENs (Supplementary Figure S6–
S8), owing to an inability to generate TALE domains ca-
pable of selectively binding mutant mtDNA, it seems likely
that an approach to achieve optimal dosage of mtTALENs
specific to a mutant haplotype could be of similar benefit
to that seen for mtZFNs. Future applications of mitochon-
drially targeted nuclease technologies appear, at least in the
short-term, to be progressing most quickly towards ther-
apy for diseases arising fromheteroplasmicmutantmtDNA
(59). The most likely, and current gold standard modality
for delivering such a form of genetic therapy is the recom-
binant adeno-associated virus (AAV), and tissue-specific
serotypes thereof. Although the AAV is generally consid-
ered to be a transient, non-integrating genetic medium, it
has been shown in animal models that viral genomes per-
sist, in an episomal state, for essentially the entire life-span
of the lab animal, most reliably in post-mitotic or slowly-
dividing tissues (60). In the context of the rapid, destructive
effects of transient expression that any mitochondrially tar-
geted nuclease can achieve within 24 h, according to our
data, it seems likely that exerting a fine level of control over
these designer enzymes will be key to achieving any success-
ful therapeutic outcome.
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